Singapore markets closed

Acelyrin, Inc. (SLRN)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
4.8800-0.1400 (-2.79%)
At close: 04:00PM EDT
4.8800 0.00 (0.00%)
After hours: 04:02PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close5.0200
Open5.0000
Bid4.8500 x 400
Ask4.9200 x 500
Day's range4.7600 - 5.0700
52-week range4.7600 - 29.8800
Volume1,195,769
Avg. volume1,232,082
Market cap480.021M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-5.4300
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est24.17
  • Simply Wall St.

    Acelyrin Insiders Placed Bullish Bets Worth US$2.65m

    Quite a few insiders have dramatically grown their holdings in Acelyrin, Inc. ( NASDAQ:SLRN ) over the past 12 months...

  • GlobeNewswire

    ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights

    Reported positive Phase 1/2 proof-of-concept data for lonigutamab, first subcutaneous anti-IGF-1R to demonstrate clinical responses in thyroid eye disease patients Achieved primary endpoint with high statistical significance in global Phase 2b/3 clinical trial of izokibep in psoriatic arthritis with robust clinical responses also achieved for higher hurdle endpoints Announced differentiated long-term 32-week data from global Phase 2b clinical trial of izokibep in hidradenitis suppurativa – ongoi

  • GlobeNewswire

    Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million

    Avalo acquires Phase 2-ready anti-IL-1β mAb, AVTX-009, through acquisition of AlmataBio, Inc. Topline results from planned Phase 2 trial in hidradenitis suppurativa expected in 2026Executed private placement financing of up to $185 million, including initial upfront investment of $115.6 million; expected to extend cash runway into 2027 Webcast to be held tomorrow, March 28, 2024 at 8:30 a.m. E.T. WAYNE, Pa. and ROCKVILLE, Md., March 27, 2024 (GLOBE NEWSWIRE) -- Avalo Therapeutics, Inc. (Nasdaq: